SARS-CoV-2 Vaccine Response in Patients With Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis

Lauren Floyd1, Mohamed E. Elsayed1, Tobias Seibt2, Anke von Bergwelt-Baildon2, Philip Seo3, Brendan Antiochos3, Sam Kant4, Adam Morris1, Ajay Dhaygude1, Ulf Schönermarck2 and Duvuru Geetha3,4

1Department of Nephrology, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK; 2Nephrology Division, Department of Medicine IV, University Hospital, LMU Munich, Munich, Germany; 3Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA; and 4Division of nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA

Correspondence: Duvuru Geetha, Department of Medicine, Johns Hopkins University School of Medicine, 301 Mason Lord Drive, Baltimore, Maryland 21224, USA. E-mail: gduvura@jhmi.edu

INTRODUCTION

The development of COVID-19 vaccines and mass vaccination is a landmark achievement of modern medicine. Management of patients with antineutrophil cytoplasmic autoantibodies–associated vasculitis (AAV) during the pandemic has been challenging. Immunosuppressive medications to control vasculitis are associated with severe COVID-19 infection and may impair immune response to the vaccine.

During the course of the pandemic, the treatment of patients with AAV has varied across the world with regard to both induction of remission and maintenance treatments.1,2

COVID-19 vaccination has been successfully implemented among patients with AAV given their vulnerability to severe infection. In our study, we aim to identify correlations between serologic tests carried out for anti–SARS-CoV-2 spike antibodies and immunosuppressive medications used in the management of AAV.

RESULTS

A total of 159 patients were included with a mean (SD) age of 65 (14) years. The average time from diagnosis of AAV was 7 years (±6). Most patients had AAV with multisystem involvement. Clinical characteristics, comorbidities, and correlation with anti–SARS-CoV-2 spike antibodies are illustrated in Table 1.

In total, 155 patients (97%) received full immunization with 1 dose of the Johnson & Johnson or both doses of Oxford-AstraZeneca, Pfizer-BioNTech, or Moderna mRNA vaccines. The mean time between the first and second doses of Pfizer-BioNTech mRNA or Moderna mRNA vaccines was 33.7 ± 19.9 days, whereas it was 75 ± 25.9 days for Oxford-AstraZeneca vaccines. The mean duration between the second vaccine dose and anti–SARS-CoV-2 spike antibody measurement was 49.8 ± 29.4 days across all centers.

Determinant of Humoral Response to the SARS-CoV-2 Vaccinations

There were 87 patients (55%) who developed detectable anti–SARS-CoV-2 spike antibodies. Of those with available quantitative antibody values (n = 48), the median antibody titer was 1192 U/ml (interquartile range: 109.3–2461.5 U/ml). We did not find any significant correlation between humoral response and age, sex, race, antineutrophil cytoplasmic autoantibody type, type of vaccine received, co-morbidities, or renal impairment (Table 1).

A total of 144 patients received immunosuppression during the time of their vaccination. Among those, 129 patients were treated with rituximab and half (n = 64, 49.6%) of these developed anti–SARS-CoV-2 spike antibodies (Table 1).

Rituximab and Cluster of Differentiation 19

The use of rituximab was significantly associated with poor humoral response to the COVID-19 vaccine and the absence of anti–SARS-CoV-2 spike antibodies (odds ratio [OR]: 0.31, CI: 0.12–0.74, P = 0.01), as found in Table 2. In univariate analysis, therapy with rituximab was strongly associated with poor antibody
response among those patients treated within 6 months before the first vaccine dose (OR: 0.12, CI: 0.06–0.25, \(P < 0.001\)).

There were 107 patients who had cluster of differentiation 19 (CD19) counts checked around the time of vaccination with 64 having CD19 reconstitution, and all

---

**Table 1. Demographic and clinical characteristics versus antispike antibody status after SARS-CoV-2 vaccination**

| Variables                              | Overall (N = 159) | Undetectable antispike antibodies (n = 70) | Detectable antispike antibodies (n = 87) | P value |
|----------------------------------------|-------------------|------------------------------------------|------------------------------------------|---------|
| **Demographics**                       |                   |                                          |                                          |         |
| Age, yr, mean (SD)                     | 65.5 (13.6)       | 68.7 (12.5)                              | 64.2 (14.4)                              | 0.33    |
| Sex, females, n (%)                    | 79 (49.7)         | 35 (50.0)                                | 44 (50.6)                                | 1.00    |
| Race, n (%)                            |                   |                                          |                                          |         |
| White                                  | 145 (91.2)        | 61 (87.1)                                | 82 (94.3)                                | 0.16    |
| Black                                  | 7 (4.4)           | 5 (7.1)                                  | 2 (2.3)                                  | 0.24    |
| Other                                  | 7 (4.4)           | 4 (5.7)                                  | 3 (3.4)                                  | 0.70    |
| **AAV disease characteristics, n (%)**|                   |                                          |                                          |         |
| ANCA type                              |                   |                                          |                                          |         |
| PR3                                    | 73 (45.9)         | 34 (48.6)                                | 38 (43.7)                                | 0.63    |
| MPO                                    | 83 (52.2)         | 36 (51.4)                                | 46 (52.9)                                | 0.87    |
| ANCA negative                          | 3 (1.9)           | 0 (0)                                    | 3 (3.4)                                  | 0.25    |
| Active disease                         | 13 (8.2)          | 4 (5.7)                                  | 8 (9.2)                                  | 0.55    |
| **Organ involvement, n (%)**           |                   |                                          |                                          |         |
| Renal                                  | 141 (88.7)        | 63 (90.0)                                | 76 (87.4)                                | 0.80    |
| Respiratory                            | 90 (56.6)         | 39 (55.7)                                | 49 (56.3)                                | 1.00    |
| Sinuses                                | 69 (43.4)         | 27 (38.6)                                | 41 (47.1)                                | 0.33    |
| Ophthalmic                             | 19 (11.9)         | 5 (7.1)                                  | 14 (16.1)                                | 0.14    |
| Neural                                 | 20 (12.6)         | 12 (17.1)                                | 8 (9.2)                                  | 0.15    |
| Gastrointestinal                       | 3 (1.9)           | 2 (2.9)                                  | 1 (1.1)                                  | 0.59    |
| Cardiac                                | 7 (4.4)           | 4 (5.7)                                  | 3 (3.4)                                  | 1.00    |
| Cutaneous                              | 21 (13.2)         | 7 (10.0)                                 | 13 (14.9)                                | 0.47    |
| Renal limited disease                  | 25 (15.7)         | 13 (18.6)                                | 12 (13.8)                                | 0.51    |
| **Co-morbidities, n (%)**              |                   |                                          |                                          |         |
| Hypertension                           | 112 (70.4)        | 52 (74.3)                                | 58 (66.7)                                | 0.38    |
| Diabetes mellitus                      | 21 (13.2)         | 10 (14.3)                                | 11 (12.6)                                | 0.82    |
| Cardiovascular disease                 | 39 (24.5)         | 17 (24.3)                                | 21 (24.1)                                | 1.00    |
| Respiratory disease                    | 27 (17.0)         | 14 (20.0)                                | 13 (14.9)                                | 0.52    |
| Renal transplant                       | 10 (6.3)          | 6 (8.6)                                  | 4 (4.6)                                  | 0.34    |
| eGFR                                    | 24 (15.1)         | 13 (18.6)                                | 9 (10.3)                                 | 0.17    |
| **Vaccination characteristics, n (%)**|                   |                                          |                                          |         |
| Vaccine type                           |                   |                                          |                                          |         |
| Oxford-AstraZeneca                     | 34 (21.4)         | 16 (22.9)                                | 18 (18.8)                                | 0.69    |
| Johnson & Johnson                      | 5 (3.1)           | 4 (5.7)                                  | 1 (1.2)                                  | 0.17    |
| Moderno                                | 31 (19.5)         | 12 (17.1)                                | 19 (22.4)                                | 0.55    |
| Pfizer-BioNTech                        | 89 (56.0)         | 38 (54.3)                                | 49 (57.6)                                | 0.75    |
| Days between first and second Vaccine  | 43.2 (25.3)       | 43.2 (24.7)                              | 43.2 (25.8)                              | 0.92    |
| **Current immunosuppression, n (%)**   |                   |                                          |                                          |         |
| CNI                                    | 10 (6.3)          | 6 (8.6)                                  | 4 (4.6)                                  | 0.34    |
| MMF                                    | 21 (13.2)         | 9 (12.9)                                 | 12 (13.8)                                | 1.00    |
| Azathioprine                           | 4 (2.5)           | 2 (2.9)                                  | 2 (2.3)                                  | 1.00    |
| Methotrexate                           | 1 (0.6)           | 0 (0)                                    | 1 (1.1)                                  | —       |
| Cyclophosphamide                       | 1 (0.6)           | 0 (0)                                    | 1 (1.1)                                  | —       |
| IVIG                                    | 2 (1.3)           | 1 (1.4)                                  | 1 (1.1)                                  | 1.00    |
| Steroid                                | 51 (32.1)         | 20 (28.6)                                | 30 (34.5)                                | 0.49    |
| **Rituximab therapy, n (%)**           |                   |                                          |                                          |         |
| Use of RTX                             | 129 (81.1)        | 63 (90.0)                                | 64 (73.6)                                | 0.01    |
| Vaccination within 6 mo of RTX         | 69 (43.4)         | 48 (68.6)                                | 20 (23.0)                                | <0.001  |
| Days from last RTX to first vaccine, median (IQR) | 184 (84–426) | 104 (49–167) | 374 (163–954) | <0.001  |
| Cumulative RTX dose before vaccine (g), mean (SD) | 4.42 (3.35) | 5.11 (3.16) | 3.91 (3.43) | 0.01 |
| CD19 reconstitution                    | 64 (40.3)         | 8 (11.4)                                 | 56 (64.4)                                | <0.001  |

AAV; antineutrophil cytoplasmic autoantibodies–associated vasculitis; ANCA, antineutrophil cytoplasmic autoantibodies; CD19; cluster of differentiation 19; CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate (ml/min per 1.73 m²); ESKD, end-stage kidney disease; IQR, interquartile range; IVIG, i.v. immunoglobulin; MMF, mycophenolate mofetil; MPO, myeloperoxidase; PR3; proteinase 3; RTX, rituximab.
these patients developed detectable antispikes antibodies. In univariate analysis, CD19 reconstitution was significantly associated with the likelihood of a positive humoral vaccine response (OR: 29.37, CI: 11.71–85.89, P < 0.001). The median cumulative dose of rituximab was 4000 mg (interquartile range: 2583–6770 mg). Patients with a humoral response had received a lower dose of rituximab (3.91 g vs. 5.11 g, P = 0.01) (Table 1). For every 1 g increase in the cumulative dose of rituximab given before vaccination, there was a 10% reduction in the probability of anti-SARS-CoV-2 spike seroconversion (OR: 0.89, CI: 0.79–0.99, P = 0.05) (Supplementary Table S1).

Multivariate Analysis
When adjusting for age, sex, and estimated glomerular filtration rate, the effect of a cumulative dose of rituximab on the humoral response to the vaccine had moderate significance. In model 1, a cumulative dose of rituximab < 6 g was associated with developing a humoral response (OR: 2.61, CI: 1.21–5.83, P = 0.02) (Table 2). In model 2, when including the time between rituximab administration and vaccination, the cumulative dose effect of rituximab lost statistical significance (P = 0.10). For every month between before rituximab therapy and vaccination, seroconversion rate increased by 8% (OR: 1.08, CI: 1.04–1.13, P < 0.001). In the final multivariable analysis (Table 2, model 3), we further adjusted for CD19 reconstitution. Our analysis reveals that regardless of cumulative dose or duration between last rituximab administration and vaccination, CD19 reconstitution was the best predictor for a humoral response to the vaccine (OR: 49.85, CI: 11.89–273.33, P < 0.001).

DISCUSSION
In this multicenter study, we reveal a diminished immune response to the COVID-19 vaccine in patients with AAV after immunosuppression. Approximately half of our study participants developed no humoral antibody response to the COVID-19 vaccination. B cell-depleting therapy with rituximab was associated with the poorest response. The CD19 count was the strongest predictor for seroconversion, with depletion conferring a low likelihood of antibody formation. In line with this, the cumulative dose and timing of vaccination were both significant factors. Every additional gram of rituximab given conferred a poorer response with a dose limit effect of 6 g, and dosing >6 months before vaccination was associated with a 7-fold increase in the odds of seroconversion.

Similar findings with regard to vaccine timing in the context of rituximab therapy have been found by Predecki et al. In our cohort, the cumulative dose of rituximab has a significant effect on humoral response to COVID-19 vaccination. For every 1 g increase in rituximab administered, the chance of serologic conversion after vaccination reduced by 11%. This reveals that cumulative dosing affects humoral immunity and is an important factor in patients receiving maintenance rituximab treatment.

CD19; cluster of differentiation 19; eGFR; estimated glomerular filtration rate (ml/min per 1.73 m²); OR, odds ratio; RTX, rituximab.

Table 2. Multivariate analysis of age, sex, eGFR, cumulative rituximab dose, time from rituximab to initial vaccination, and presence of CD19 reconstitution on the probability of developing a humoral response to the SARS-CoV-2 vaccination

| Model 1 | Variable               | OR 95% CI      | P value | Model 2 | Variable               | OR 95% CI      | P value | Model 3 | Variable               | OR 95% CI      | P value |
|---------|------------------------|----------------|---------|---------|------------------------|----------------|---------|---------|------------------------|----------------|---------|
| Age     | 0.99 (0.96–1.02)       | 0.68           |         | Age     | 0.98 (0.94–1.01)       | 0.19           |         | Model 1 | Age                    | 1.02 (0.96–1.08) | 0.49    |
| Male vs. female | 1.12 (0.57–2.21)   | 0.75           |         | Male vs. female | 1.49 (0.67–3.39)   | 0.33           |         | Male vs. female | 2.47 (0.83–8.10)  | 0.11    |
| eGFR    | 1.00 (0.99–1.02)       | 0.54           |         | eGFR    | 1.00 (0.98–1.02)       | 0.86           |         | eGFR    | 1.02 (0.99–1.05)       | 0.19    |
| Cumulative RTX dose < 6 g | 2.61 (1.21–5.83) | 0.02           |         | Cumulative RTX dose < 6 g | 2.10 (0.88–5.22) | 0.1      |         | Cumulative RTX dose < 6 g | 3.03 (0.94–10.76) | 0.07    |
| Months from RTX to vaccine | 1.08 (1.04–1.13) | <0.001         |         | Months from RTX to vaccine | 0.99 (0.96–1.03) | 0.62    |         | CD19 reconstitution | 49.85 (11.89–273.33) | <0.001 |

CD19 reconstitution on the probability of developing a humoral response to the SARS-CoV-2 vaccination.

<ref>Predecki et al. 1</ref>
months before vaccination had significantly higher chances of developing antibodies.

The study was limited by its relatively small sample size, differences in cumulative immunosuppressive doses, type of vaccinations, and serologic assays. Furthermore, T cell response to vaccination could not be determined. Despite this, our study cohort represents the so far largest study on humoral response to COVID-19 vaccine in patients with AAV, most of whom were treated with B cell-depleting therapy.

Our study reveals a significant negative impact of the therapy with the B cell-depleting agent, rituximab, on the anti–SARS-CoV-2 spike antibody response after vaccination. CD19 reconstitution was the most predictive marker of humoral response to the vaccine regardless of dose or duration of rituximab treatment. On the basis of these findings, it is reasonable to propose that CD19 counts can be used as a marker to aid decisions on timing and anticipated response to other vaccines in patients receiving rituximab.

DISCLOSURE
DG reports serving as a consultant to ChemoCentryx and funded by Jerome L. Greene discovery award. AD reports receiving fees for lecturing for Merck Sharp & Dohme and travel support from Pharmacosmos. US reports receiving grants and nonfinancial support from Alexion Pharma, Ablynx/Sanoﬁ, ChemoCentryx/Vifor, and Allena Pharmaceuticals. All the other authors declared no competing interests.

SUPPLEMENTARY MATERIAL
Supplementary File (PDF)
Supplementary Methods.
Table S1. Impact of AAV disease characteristics, co-morbidities, and immunosuppression on the presence of antispike antibodies after SARS-CoV-2 vaccination.
Supplementary Reference S1.

REFERENCES
1. Bruchfeld A, Kronbichler A, Alberici F, et al. COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab. Nephrol Dial Transplant. 2021;36:1758–1760. https://doi.org/10.1093/ndt/gfab174.
2. Strangfeld A, Schäfer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80:930–942. https://doi.org/10.1136/annrheumdis-2020-219488.
3. Prendecki M, Clarke C, Edwards H, et al. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann Rheum Dis. 2021;80:1322–1329. https://doi.org/10.1136/annrheumdis-2021-220626.
4. Turner-Stokes T, Sandhu E, Pepper RJ, et al. Induction treatment of ANCA-associated vasculitis with a single dose of rituximab. Rheumatology (Oxford). 2014;53:1395–1403. https://doi.org/10.1093/rheumatology/keab815.
5. Avouac J, Miceli-Richard C, Combier A, et al. Risk factors of impaired humoral response to COVID-19 vaccination in rituximab treated patients. Rheumatology (Oxford). Published online November 2, 2021. https://doi.org/10.1093/rheumatology/keab815.
6. Spiera R, Jinich S, Jannat-Khah D. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases. Ann Rheum Dis. 2021;80:1357–1359. https://doi.org/10.1136/annrheumdis-2021-220604.
7. Connolly CM, Koenig D, Ravi SN, et al. Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response” by Bonelli et al. Ann Rheum Dis. 2021;80:e164. https://doi.org/10.1136/annrheumdis-2021-220972.
8. Nazi I, Kelton JG, Larché M, Snider DP, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013;122:1946–1953. https://doi.org/10.1182/blood-2013-04-490496.
9. Kant S, Kronbichler A, Salas A, et al. Timing of COVID-19 vaccine in the setting of anti-CD20 therapy: a primer for nephrologists. Kidney Int Rep. 2021;6:1197–1199. https://doi.org/10.1016/j.ekir.2021.03.876.